The Medium Effective Volume of 0.375% Ropivacaine for Ultrasound-guided Anterior Suprascapular Nerve Block (aSSNB) in Arthroscopic Shoulder Surgery, a Single-armed, Prospective, dose-finding Study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061773

Enrollment

Unknown

Registered

2022-07-02

Start date

2021-09-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The Experiment Group:different volume of 0.375% ropivacaine

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Scheduled for arthroscopic shoulder surgery; 2. ASA I-II; 3. Age between 18-70 years old; 4. BMI between 18-30 kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Paitiens with following condition: Injection site infection, sepsis, coagulation defects, local anesthetic allergy, uncontrolled hypertension, ischemic heart disease, a sequel of cerebral infarction, liver or renal failure, and history of surgery in the supraclavicular fossa; 2. the patient refused to give consent.

Design outcomes

Primary

Measure	Time frame
Medium Effective Volume;	—

Secondary

Measure	Time frame
24h sufentanil consumption;24h PCA Presses;diaphram movement;	—

Countries

China

Contacts

Public ContactYong Zhang

zhangyongjxz@163.com+86 13770557940

Outcome results